title: CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer.
abstract: BACKGROUND
  The CHD5 gene located on 1p36 encodes a protein-chromodomain helicase DNA-binding protein 5. CHD5 has been shown to be a tumor suppressor gene candidate. This study investigated the involvement of CHD5 in ovarian cancer and its clinicopathological significance.
  
  
  METHODS
  CHD5 expression in ovarian cancer and its counterpart were determined by quantitative RT-PCR. The correlation of CHD5 expression to clinicopathological features of the tumor was analyzed.
  
  
  RESULTS
  CHD5 expression was downregulated by at least twofold in 32 of 72 (41%) invasive epithelial ovarian carcinomas when compared to 12 controls in Hong Kong Chinese women. CHD5 downregulation was correlated to clinical status (p < 0.05), but not to patient age, tumor type and grade, recurrence and clinical stage (p > 0.05). Survival analysis showed that patients with CHD5 downregulation in their tumors were associated with shorter disease-free and total survival times compared to those without CHD5 downregulation (p < 0.05). Cox proportional-hazards regression analysis indicated that downregulation of CHD5 is an independent adverse prognostic factor in ovarian cancer.
  
  
  CONCLUSIONS
  This study shows that CHD5 is downregulated in a certain number of ovarian cancers and appears to be an adverse predictor candidate of ovarian cancer disease-free and total survival.
authors.affiliation: Departments of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, SAR, China.
authors.forename: Raymond R Y
authors.initials: RR
authors.lastname: Wong
authors.forename: Loucia K Y
authors.initials: LK
authors.lastname: Chan
authors.forename: Teresa P T
authors.initials: TP
authors.lastname: Tsang
authors.forename: Coral W S
authors.initials: CW
authors.lastname: Lee
authors.forename: T H
authors.initials: TH
authors.lastname: Cheung
authors.forename: S F
authors.initials: SF
authors.lastname: Yim
authors.forename: Nelson S S
authors.initials: NS
authors.lastname: Siu
authors.forename: Sophia N C
authors.initials: SN
authors.lastname: Lee
authors.forename: M Y
authors.initials: MY
authors.lastname: Yu
authors.forename: Stephen S C
authors.initials: SS
authors.lastname: Chim
authors.forename: Y F
authors.initials: YF
authors.lastname: Wong
authors.forename: Tony K H
authors.initials: TK
authors.lastname: Chung
mesh_terms: D000077216:Carcinoma, Ovarian Epithelial; D016022:Case-Control Studies; D004265:DNA Helicases / Q000235:genetics*; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D009419:Nerve Tissue Proteins / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D060888:Real-Time Polymerase Chain Reaction; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis
chemical_list: D009419:Nerve Tissue Proteins; D004265:DNA Helicases; C471926:CHD5 protein, human